Logo do repositório
 
Publicação

SARS-CoV-2 serological 6-months follow-up study of a hospital-based cohort of healthcare workers following 2023 COVID-19 vaccination program

2024-09-24Documento de conferência Acesso aberto
Ver registo simples
dc.contributor.authorSantos, João Almeida
dc.contributor.authorGaio, Vânia
dc.contributor.authorAmaral, Palmira
dc.contributor.authorHenriques, Camila
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorMachado, Ausenda
dc.date.accessioned2026-06-16T10:07:40Z
dc.date.available2026-06-16T10:07:40Z
dc.date.issued2024-09-24
dc.description.abstractObjective: Healthcare workers (HCWs) have a higher risk of SARS-CoV-2 infection due to their direct contact with patients. On the other hand, they can also act as a source of in-hospital transmission. We assessed SARS-CoV-2 serological status of HCWs at a Portuguese central hospital before vaccination, three and six months after the 2023 COVID-19 booster vaccination program. Methods: We conducted a serological follow-up study among a cohort of HCWs from a Portuguese central hospital, with three rounds of testing: pre-COVID-19 vaccination (September/October 2023), three months (January/February 2024), and six months (April/May 2024) post-vaccination. During follow-up, only participants who underwent pre-vaccination serology and were vaccinated were included. SARS-CoV-2 spike receptor-binding domain (anti-RBD/S) protein-specific IgG antibodies were measured (upper limit of detection 40000 AU/mL). Descriptive statistics and Pearson Chi-Square test analysis were performed. Results: All participants (n=177, median age: 47 years, 77,4% females) had the complete primary COVID-19 vaccination with 78,0% having received 2 additional booster doses prior to 2023 vaccination program. At pre-vaccination, all HCWs had anti-RBD/S IgG antibodies with 11,9% (n=21) presenting a concentration >40000 AU/mL. Three months later, 35,0% HCWs (n=62) underwent retesting, with 40,3% presenting anti-RBD/S IgG antibody concentrations >40000 AU/mL. After six months, 26,6% HCWs (n=47) repeated testing, with 21,3% (n=10) having antibody concentrations >40000 AU/mL. The differences in anti-RBD/S IgG antibody concentrations between the three rounds of testing were significant. Conclusions: Three months post-COVID-19 2023 autumn vaccination, an increase in the concentration of anti-RBD/S antibodies was identified among HCW, but after six months this concentration decreased. These results are in line with the expected decay of antibodies over time after 3 months of vaccination and reinforce the importance of revaccination in HCWs.pt_PT
dc.description.sponsorshipThis study was funded by European Centre for Disease Prevention and Control through “Vaccine Effectiveness, Burden and Impact Studies” (VEBIS) Lot 2 “Assessment of COVID-19 and influenza vaccine effectiveness among healthcare workers” framework contract ECDC/2021/017.
dc.description.versionN/Apt_PT
dc.identifier.urihttp://hdl.handle.net/10400.18/11331
dc.language.isoengpt_PT
dc.peerreviewedn/a
dc.rights.uriN/A
dc.subjectSARS-CoV-2pt_PT
dc.subjectCOVID-19
dc.subjectSerological Statuspt_PT
dc.subjectVaccinespt_PT
dc.subjectVEBIS
dc.subjectPublic Healthpt_PT
dc.subjectEstados de Saúde e de Doençapt_PT
dc.subjectInfecções Respiratórias
dc.titleSARS-CoV-2 serological 6-months follow-up study of a hospital-based cohort of healthcare workers following 2023 COVID-19 vaccination programpt_PT
dc.typeconference object
dspace.entity.typePublication
oaire.citation.conferenceDate2024-09-24
oaire.citation.conferencePlaceÉvora, Portugal
oaire.citation.title5th CHRC Annual Summit, 23,24 September 2024
oaire.versionhttp://purl.org/coar/version/c_b1a7d7d4d402bcce
person.familyNameAlmeida Santos
person.familyNameGaio
person.familyNameValadas Henriques
person.familyNameGuiomar
person.familyNameMachado
person.givenNameJoão
person.givenNameVânia
person.givenNameCamila
person.givenNameRaquel
person.givenNameAusenda
person.identifier1709999
person.identifier.ciencia-id9012-DD7F-745F
person.identifier.ciencia-idA71A-17AF-30C7
person.identifier.ciencia-id851F-4E5E-D0AD
person.identifier.ciencia-idAE10-5FAB-7439
person.identifier.ciencia-id1217-6076-5D88
person.identifier.orcid0000-0002-8564-1098
person.identifier.orcid0000-0001-7626-4991
person.identifier.orcid0000-0002-3654-4929
person.identifier.orcid0000-0002-4563-6315
person.identifier.orcid0000-0002-1849-1499
person.identifier.scopus-author-id57210569889
person.identifier.scopus-author-id56080468200
rcaap.rightsclosedAccesspt_PT
rcaap.typelecturept_PT
relation.isAuthorOfPublicationd1a7b2d4-9a19-4a3a-9389-fd049d8db5ca
relation.isAuthorOfPublication59791814-187c-4b34-b3a2-6ad67a213814
relation.isAuthorOfPublication6fe03523-acfc-4a28-ba2d-ab0d9b911d1e
relation.isAuthorOfPublication9743082d-bed6-4e5e-94f5-1d27bb037bb0
relation.isAuthorOfPublication544ad266-0c22-4a50-9ebc-86acc08d6666
relation.isAuthorOfPublication.latestForDiscovery544ad266-0c22-4a50-9ebc-86acc08d6666

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
SPK_CO CHRC vf.pdf
Tamanho:
491.56 KB
Formato:
Adobe Portable Document Format
Descrição:
Comunicação oral
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

DEP - Apresentações orais em encontros nacionais
DDI - Posters/abstracts em congressos nacionais